沙利度胺联合常规化疗治疗急性髓细胞白血病的效果

Abstract
Figure/Table
References (18)
Related Citation (4)

Download: PDF (0 KB) HTML (46 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo investigate the effect of Thalidomide combined with conventional chemotherapy treating acute myeloid leukemia(AML).MethodsSixty-three newly diagnosed AML in our hospital from January to December 2013 were selected.They were divided into Thalidomide combined with routine chemotherapy group(combined group,35 cases)and routine chemotherapy group(control group,28 cases).All patients were treated with DA chemotherapy regimen for 4 courses (7 d for a course of treatment),while the combined group was given thalidomide for 4 months.The changes of VEGF, VEGFR,bFGF,MVD and the long-term survival status in the two groups were recorded and compared,the efficacy and incidence of adverse reactions were analyzed.ResultsThe effective rate in the combined group was 88.57%,and it was significantly higher than 60.71%in the control group(P<0.05).After treatment,the level of VEGF,VEGFR,bFGF and MVD in the two groups were significantly lower than those before treatment(P<0.05).And the level of VEGF,VEGFR and MVD in the combined group were significantly lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05)besides digestive system symptoms,which in the combined group(65.71%)was significantly higher than that in the control group(17.86%).ConclusionThe therapy of Thalidomide combined with conventional chemotherapy can effectively inhibit the expression of VEGF and VEGFR and the production of bone marrow microvessels in patients with AML.But it had no significant effect on the patients′long-term survival rate.

Key words： Thalidomide Acute myeloid leukemia Vascular endothelial growth factor Basic fibroblast growth factor Bone marrow microvessel density Long-term survival rate

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Li-yi

Cite this article:

ZHANG Li-yi. Effect of Thalidomide combined with conventional chemotherapy treating acute myeloid leukemia[J]. 中国当代医药, 2017, 24(11): 31-34.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I11/31

[1]	何海涛，李惠民.急性髓系白血病靶向治疗的研究进展[J].中国实验血液学杂志，2016，24（1）：245-249.
[2]	张王刚，白菊.急性髓系白血病免疫治疗的研究进展与展望[J].西安交通大学学报（医学版），2015，36（5）：573-579.
[3]	刘婉文，廖友明，万忠和，等.血管内皮生长因子及其受体Flt、KDR的表达水平与儿童急性白血病的关系研究[J].中华医院感染学杂志，2016，26（14）：3313-3315.
[4]	Gora-Tybor J，Szemraj J，Robak T，et al.Clinical relevance ofvascularendothelialgrowthfactortypeA（VEGFA）andVEGF receptortype2（VEGFR2）gene polymorphism in chronic lymphocytic leukemia[J].Blood Cells Mol Dis，2015，54（2）：139-143.
[5]	Popat R，Brown SR，Flanagan L，et al.Bortezomib，thalidomide，dexamethasone，and panobinostat for patients with relapsed multiple myeloma（MUK-six）：a multicentre，open-label，phase 1/2 trial[J].Lancet Haematol，2016，3（12）：e572-e580.
[6]	Luo J，Gagne JJ，Landon J，et al.Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America：a population-based cohort study[J].Eur J Cancer，2017，70：22-33.
[7]	张之南，郝玉书，赵永强，等.血液病学[M].北京：人民卫生出版社，2011：1674.
[8]	夏轶姿，陈莹，王征.参芪扶正注射液联合沙利度胺对急性髓细胞白血病外周血调节性T细胞比例的影响研究[J].中华中医药学刊，2016，34（5）：1215-1217.
[9]	王琦，韩艳秋.急性早幼粒细胞白血病诊治的回顾及进展[J].中华临床医师杂志（电子版），2012，6（2）：419-422.
[10]	Eichholz A，Merchant S，Gaya AM.Anti-angiogenesis therapies：their potential in cancer management[J].Onco Targets Ther，2010，3：69-82.
[11]	王学文.超低剂量沙利度胺治疗多发性骨髓瘤的临床研究[J].现代肿瘤医学，2011，19（6）：1253-1255.
[12]	Reikvam H，Nepstad I，Sulen A，et al.Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors[J].Expert Opin Investig Drugs，2013，22（5）：551-563.
[13]	El-Aarag B，Kasai T，Masuda J，et al.Anticancer effects of novel thalidomide analogs in A549 cells through inhibition of vascular endothelial growth factor and matrix metalloproteinase-2[J].Biomed Pharmacother，2017，85：549-555.
[14]	Lopesaguiar L，Delamain MT，Brito ABC，et al.VEGF，VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients in the thalidomide era[J].Clin Lymphoma Myeloma Leuk，2016，16：S70-S71.
[15]	蔡植华，郑乃莹，柳子川.沙利度胺联合常规化疗治疗急性白血病的疗效观察[J].现代中西医结合杂志，2015，24（15）：1631-1633.
[16]	何牧卿，何牧群，林晓骥.沙利度胺联合化疗治疗白血病临床疗效研究[J].中华全科医学，2014，12（8）：1199-1201.
[18]	韩泽.分析沙利度胺联合常规化疗治疗急性白血病的疗效[J].中国实用医药，2016，11（28）：162-163.
[17]	Buchner T，Berdel WE，Haferlach C，et al.Age-related risk profile and chemotherapy dose response in acute myeloid leukemia：a study by the German Acute Myeloid Leukemia Cooperative Group[J].J Clin Oncol，2009，27（1）：61-69.